No Benefit For Liver Cancer Patients From Long-Acting Octreotide

Published: Jan 03, 2007

Long-acting octreotide does not improve outcomes for patients with liver cancer compared to a placebo, according to the results of a new double blind study published in the January 2007 issue of Hepatology, the official journal of the American Association for the Study of Liver Diseases (AASLD). Published by John Wiley & Sons, Inc., the journal is available online via Wiley InterScience (http://www.interscience.wiley.com/journal/hepatology).

>>> Discuss This Story

Back to news